Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer
Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer
复制标题
DOI：
10.1038/sj.bjc.6600943
复制
发表时间：
2003-05-19
影响因子：
8.8
通讯作者：
Couturier, J
中科院分区：
文献类型：
--
作者：
Arnould, L;Denoux, Y;Couturier, J
确定乳腺癌中的HER 2/neu（HER 2）状态对于选择接受曲妥珠单抗治疗的乳腺癌患者是必要的。通过荧光原位杂交（FISH）分析的基因扩增或通过免疫组织化学（IHC）确定的蛋白质过表达是建立这种状态的两种主要方法。先前已经证明了这两种方法之间的强相关性。然而，FISH在常规实践中并不总是可行的，弱阳性IHC肿瘤（2+）并不总是对应于基因扩增。我们的研究是为了评估显色原位杂交（CISH）的贡献，它可以通过免疫过氧化物酶反应检测基因拷贝。在79例乳腺癌中进行了CISH，这些乳腺癌先前通过IHC和FISH确定了HER 2状态。比较了每种肿瘤的IHC、FISH和CISH结果。CISH手术在95%的病例中获得成功。无论IHC结果如何，我们发现CISH和FISH之间的一致性非常好（96%）。我们的研究证实，CISH可能是FISH的替代方法，用于确定2+肿瘤的基因扩增状态。我们的研究结果使我们认为，在许多实验室中，CISH也可能是校准IHC程序或作为质量控制测试的一种极好的方法，可以定期检查IHC信号是否与基因状态一致。
Determination of the HER2/neu (HER2) status in breast carcinoma has become necessary for the selection of breast cancer patients for trastuzumab therapy. Amplification of the gene analysed by fluorescence in situ hybridisation ( FISH) or overexpression of the protein determined by immunohistochemistry (IHC) are the two major methods to establish this status. A strong correlation has been previously demonstrated between these two methods. However, FISH is not always feasible in routine practice and weakly positive IHC tumours (2+) do not always correspond to a gene amplification. Our study was performed in order to evaluate the contribution of chromogenic in situ hybridisation ( CISH), which enables detection of the gene copies through an immunoperoxidase reaction. CISH was performed in 79 breast carcinomas for which the HER2 status was previously determined by IHC and FISH. The results of IHC, FISH and CISH were compared for each tumour. CISH procedures were successful in 95% of our cases. Whatever the IHC results, we found a very good concordance (96%) between CISH and FISH. Our study confirms that CISH may be an alternative to FISH for the determination of the gene amplification status in 2+ tumours. Our results allow us to think that, in many laboratories, CISH may also be an excellent method to calibrate the IHC procedures or, as a quality control test, to check regularly that the IHC signal is in agreement with the gene status.